Canaccord Genuity Group reiterated their buy rating on shares of Diaceutics (LON:DXRX – Free Report) in a research note issued to investors on Tuesday morning,Digital Look reports. The brokerage currently has a GBX 215 price objective on the stock.
Diaceutics Stock Performance
LON DXRX opened at GBX 190 on Tuesday. The business has a 50 day moving average price of GBX 188.20 and a 200 day moving average price of GBX 160.85. The company has a market capitalization of £161.45 million, a P/E ratio of -593.75 and a beta of 0.88. Diaceutics has a 1-year low of GBX 125 and a 1-year high of GBX 210. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92.
Diaceutics (LON:DXRX – Get Free Report) last announced its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) earnings per share for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. Sell-side analysts expect that Diaceutics will post 1.01 EPS for the current fiscal year.
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.
Further Reading
- Five stocks we like better than Diaceutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.
